Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Cybin NASDAQ: HELP outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026.

MarketBeat • Oct 21, 2026

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Helus Pharma Inc. (HELP) Discusses Clinical Pipeline and Phase 3 Strategies for Novel Serotonergic Agonists in Mental Health Transcript

Seeking Alpha • Oct 21, 2026

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2

GlobeNewsWire • Oct 21, 2026

Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 20, 2026

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

GlobeNewsWire • Oct 15, 2026

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.

Seeking Alpha • Oct 11, 2026

Helus Pharma to Host Investor Presentation on October 21, 2026

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.

GlobeNewsWire • Oct 8, 2026

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company's annual and special meeting of shareholders held on September 22, 2026.

GlobeNewsWire • Oct 1, 2026

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.

MarketBeat • Sep 24, 2026

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.

MarketBeat • Sep 22, 2026